Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Blättler WA[au]:

Search results

Items: 1 to 50 of 55

1.

Developing drug molecules for therapy with carbon monoxide.

Romão CC, Blättler WA, Seixas JD, Bernardes GJ.

Chem Soc Rev. 2012 May 7;41(9):3571-83. doi: 10.1039/c2cs15317c. Epub 2012 Feb 20. Review.

PMID:
22349541
2.

Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate.

Lewis Phillips GD, Li G, Dugger DL, Crocker LM, Parsons KL, Mai E, Blättler WA, Lambert JM, Chari RV, Lutz RJ, Wong WL, Jacobson FS, Koeppen H, Schwall RH, Kenkare-Mitra SR, Spencer SD, Sliwkowski MX.

Cancer Res. 2008 Nov 15;68(22):9280-90. doi: 10.1158/0008-5472.CAN-08-1776.

3.

Semisynthetic maytansine analogues for the targeted treatment of cancer.

Widdison WC, Wilhelm SD, Cavanagh EE, Whiteman KR, Leece BA, Kovtun Y, Goldmacher VS, Xie H, Steeves RM, Lutz RJ, Zhao R, Wang L, Blättler WA, Chari RV.

J Med Chem. 2006 Jul 13;49(14):4392-408.

PMID:
16821799
4.

Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing.

Erickson HK, Park PU, Widdison WC, Kovtun YV, Garrett LM, Hoffman K, Lutz RJ, Goldmacher VS, Blättler WA.

Cancer Res. 2006 Apr 15;66(8):4426-33.

5.

Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen.

Kovtun YV, Audette CA, Ye Y, Xie H, Ruberti MF, Phinney SJ, Leece BA, Chittenden T, Blättler WA, Goldmacher VS.

Cancer Res. 2006 Mar 15;66(6):3214-21.

6.

In vivo behaviour of antibody-drug conjugates for the targeted treatment of cancer.

Xie H, Blättler WA.

Expert Opin Biol Ther. 2006 Mar;6(3):281-91. Review.

PMID:
16503736
7.

Structural characterization of the maytansinoid-monoclonal antibody immunoconjugate, huN901-DM1, by mass spectrometry.

Wang L, Amphlett G, Blättler WA, Lambert JM, Zhang W.

Protein Sci. 2005 Sep;14(9):2436-46. Epub 2005 Aug 4.

8.

Analysis of the composition of immunoconjugates using size-exclusion chromatography coupled to mass spectrometry.

Lazar AC, Wang L, Blättler WA, Amphlett G, Lambert JM, Zhang W.

Rapid Commun Mass Spectrom. 2005;19(13):1806-14.

PMID:
15945030
9.

Pharmacokinetics and biodistribution of the antitumor immunoconjugate, cantuzumab mertansine (huC242-DM1), and its two components in mice.

Xie H, Audette C, Hoffee M, Lambert JM, Blättler WA.

J Pharmacol Exp Ther. 2004 Mar;308(3):1073-82. Epub 2003 Nov 21. Erratum in: J Pharmacol Exp Ther. 2004 Aug;310(2):844.

PMID:
14634038
10.

An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation.

Maloney EK, McLaughlin JL, Dagdigian NE, Garrett LM, Connors KM, Zhou XM, Blättler WA, Chittenden T, Singh R.

Cancer Res. 2003 Aug 15;63(16):5073-83.

11.

Anti-B4-blocked ricin: a phase II trial of 7 day continuous infusion in patients with multiple myeloma.

Grossbard ML, Fidias P, Kinsella J, O'Toole J, Lambert JM, Blattler WA, Esseltine D, Braman G, Nadler LM, Anderson KC.

Br J Haematol. 1998 Jul;102(2):509-15.

PMID:
9695966
12.

Immunotoxin therapy of small-cell lung cancer: a phase I study of N901-blocked ricin.

Lynch TJ Jr, Lambert JM, Coral F, Shefner J, Wen P, Blattler WA, Collinson AR, Ariniello PD, Braman G, Cook S, Esseltine D, Elias A, Skarin A, Ritz J.

J Clin Oncol. 1997 Feb;15(2):723-34.

PMID:
9053498
13.

Identification of domains of the insulin-like growth factor I receptor that are required for protection from apoptosis.

O'Connor R, Kauffmann-Zeh A, Liu Y, Lehar S, Evan GI, Baserga R, Blättler WA.

Mol Cell Biol. 1997 Jan;17(1):427-35.

14.

A comparison of two murine monoclonal antibodies humanized by CDR-grafting and variable domain resurfacing.

Roguska MA, Pedersen JT, Henry AH, Searle SM, Roja CM, Avery B, Hoffee M, Cook S, Lambert JM, Blättler WA, Rees AR, Guild BC.

Protein Eng. 1996 Oct;9(10):895-904. Erratum in: Protein Eng 1997 Feb;10(2):181.

PMID:
8931129
15.

Eradication of large colon tumor xenografts by targeted delivery of maytansinoids.

Liu C, Tadayoni BM, Bourret LA, Mattocks KM, Derr SM, Widdison WC, Kedersha NL, Ariniello PD, Goldmacher VS, Lambert JM, Blättler WA, Chari RV.

Proc Natl Acad Sci U S A. 1996 Aug 6;93(16):8618-23.

16.

Cure of multidrug-resistant human B-cell lymphoma xenografts by combinations of anti-B4-blocked ricin and chemotherapeutic drugs.

Liu C, Lambert JM, Teicher BA, Blättler WA, O'Connor R.

Blood. 1996 May 1;87(9):3892-8.

PMID:
8611717
17.

Formation of N-substituted 2-iminothiolanes when amino groups in proteins and peptides are modified by 2-iminothiolane.

Singh R, Kats L, Blättler WA, Lambert JM.

Anal Biochem. 1996 Apr 5;236(1):114-25.

PMID:
8619475
18.

Anti-B4-blocked ricin synergizes with doxorubicin and etoposide on multidrug-resistant and drug-sensitive tumors.

O'Connor R, Liu C, Ferris CA, Guild BC, Teicher BA, Corvi C, Liu Y, Arceci RJ, Goldmacher VS, Lambert JM, Blättler WA.

Blood. 1995 Dec 1;86(11):4286-94.

PMID:
7492789
19.

Enhancement of the selectivity and antitumor efficacy of a CC-1065 analogue through immunoconjugate formation.

Chari RV, Jackel KA, Bourret LA, Derr SM, Tadayoni BM, Mattocks KM, Shah SA, Liu C, Blättler WA, Goldmacher VS.

Cancer Res. 1995 Sep 15;55(18):4079-84.

20.

Expression and secretion of a recombinant ricin immunotoxin from murine myeloma cells.

Krek CE, Ladino CA, Goldmacher VS, Blättler WA, Guild BC.

Protein Eng. 1995 May;8(5):481-9.

PMID:
8532670
21.

Assay for thiols based on reactivation of papain.

Singh R, Blättler WA, Collinson AR.

Methods Enzymol. 1995;251:229-37. No abstract available.

PMID:
7651201
22.

Elimination of B-lineage leukemia and lymphoma cells from bone marrow grafts using anti-B4-blocked-ricin immunotoxin.

Roy DC, Perreault C, Bélanger R, Gyger M, Le Houillier C, Blättler WA, Lambert JM, Ritz J.

J Clin Immunol. 1995 Jan;15(1):51-7.

PMID:
7539011
23.

Mutational and structural analysis of the lectin activity in binding domain 2 of ricin B chain.

Lehar SM, Pedersen JT, Kamath RS, Swimmer C, Goldmacher VS, Lambert JM, Blättler WA, Guild BC.

Protein Eng. 1994 Oct;7(10):1261-6.

PMID:
7855142
24.

Humanization of murine monoclonal antibodies through variable domain resurfacing.

Roguska MA, Pedersen JT, Keddy CA, Henry AH, Searle SJ, Lambert JM, Goldmacher VS, Blättler WA, Rees AR, Guild BC.

Proc Natl Acad Sci U S A. 1994 Feb 1;91(3):969-73.

25.

Preparation and characterization of interleukin-2-gelonin conjugates made using different cross-linking reagents.

McIntyre GD, Scott CF Jr, Ritz J, Blättler WA, Lambert JM.

Bioconjug Chem. 1994 Jan-Feb;5(1):88-97.

PMID:
8199239
26.

An amplified assay for thiols based on reactivation of papain.

Singh R, Blättler WA, Collinson AR.

Anal Biochem. 1993 Aug 15;213(1):49-56.

PMID:
8238881
27.

Adjuvant immunotoxin therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with B-cell non-Hodgkin's lymphoma.

Grossbard ML, Gribben JG, Freedman AS, Lambert JM, Kinsella J, Rabinowe SN, Eliseo L, Taylor JA, Blättler WA, Epstein CL, et al.

Blood. 1993 May 1;81(9):2263-71.

PMID:
8481509
28.

Anti-B4-blocked ricin: a phase I trial of 7-day continuous infusion in patients with B-cell neoplasms.

Grossbard ML, Lambert JM, Goldmacher VS, Spector NL, Kinsella J, Eliseo L, Coral F, Taylor JA, Blättler WA, Epstein CL, et al.

J Clin Oncol. 1993 Apr;11(4):726-37.

PMID:
7683045
29.

Anti-B4-blocked ricin immunotoxin shows therapeutic efficacy in four different SCID mouse tumor models.

Shah SA, Halloran PM, Ferris CA, Levine BA, Bourret LA, Goldmacher VS, Blättler WA.

Cancer Res. 1993 Mar 15;53(6):1360-7.

30.

Correlation between in vivo toxicity and preclinical in vitro parameters for the immunotoxin anti-B4-blocked ricin.

Grossbard ML, Lambert JM, Goldmacher VS, Blättler WA, Nadler LM.

Cancer Res. 1992 Aug 1;52(15):4200-7.

31.

Phage display of ricin B chain and its single binding domains: system for screening galactose-binding mutants.

Swimmer C, Lehar SM, McCafferty J, Chiswell DJ, Blättler WA, Guild BC.

Proc Natl Acad Sci U S A. 1992 May 1;89(9):3756-60.

32.

Effects of anti-CD33 blocked ricin immunotoxin on the capacity of CD34+ human marrow cells to establish in vitro hematopoiesis in long-term marrow cultures.

La Russa VF, Griffin JD, Kessler SW, Cutting MA, Knight RD, Blattler WA, Lambert JM, Wright DG.

Exp Hematol. 1992 May;20(4):442-8.

PMID:
1373688
34.

Expression of the receptor-linked protein tyrosine phosphatase LAR: proteolytic cleavage and shedding of the CAM-like extracellular region.

Streuli M, Krueger NX, Ariniello PD, Tang M, Munro JM, Blattler WA, Adler DA, Disteche CM, Saito H.

EMBO J. 1992 Mar;11(3):897-907.

35.

Photoactivation of toxin conjugates.

Goldmacher VS, Senter PD, Lambert JM, Blättler WA.

Bioconjug Chem. 1992 Mar-Apr;3(2):104-7.

PMID:
1515463
36.

Serotherapy of B-cell neoplasms with anti-B4-blocked ricin: a phase I trial of daily bolus infusion.

Grossbard ML, Freedman AS, Ritz J, Coral F, Goldmacher VS, Eliseo L, Spector N, Dear K, Lambert JM, Blättler WA, et al.

Blood. 1992 Feb 1;79(3):576-85.

PMID:
1370636
37.

Immunoconjugates containing novel maytansinoids: promising anticancer drugs.

Chari RV, Martell BA, Gross JL, Cook SB, Shah SA, Blättler WA, McKenzie SJ, Goldmacher VS.

Cancer Res. 1992 Jan 1;52(1):127-31.

38.

An immunotoxin prepared with blocked ricin: a natural plant toxin adapted for therapeutic use.

Lambert JM, Goldmacher VS, Collinson AR, Nadler LM, Blättler WA.

Cancer Res. 1991 Dec 1;51(23 Pt 1):6236-42.

39.

Anti-MY9-blocked-ricin: an immunotoxin for selective targeting of acute myeloid leukemia cells.

Roy DC, Griffin JD, Belvin M, Blättler WA, Lambert JM, Ritz J.

Blood. 1991 Jun 1;77(11):2404-12.

PMID:
2039821
40.
41.
42.

Realizing the full potential of immunotoxins.

Blättler WA, Lambert JM, Goldmacher VS.

Cancer Cells. 1989 Oct;1(2):50-5. Review.

PMID:
2701364
43.

Cytotoxicity of gelonin and its conjugates with antibodies is determined by the extent of their endocytosis.

Goldmacher VS, Scott CF, Lambert JM, McIntyre GD, Blättler WA, Collnhson AR, Stewart JK, Chong LD, Cook S, Slayter HS, et al.

J Cell Physiol. 1989 Oct;141(1):222-34.

PMID:
2528553
44.
45.

Requirements for the construction of antibody heterodimers for the direction of lysis of tumors by human T cells.

Scott CF Jr, Blättler WA, Lambert JM, Kalish RS, Morimoto C, Schlossman SF.

J Clin Invest. 1988 May;81(5):1427-33.

46.

Purification and biochemical characterization of immunotoxins.

Lambert JM, Blättler WA.

Cancer Treat Res. 1988;37:323-48. Review.

PMID:
2908631
47.

Immunotoxins containing single-chain ribosome-inactivating proteins.

Lambert JM, Blättler WA, McIntyre GD, Goldmacher VS, Scott CF Jr.

Cancer Treat Res. 1988;37:175-209. Review.

PMID:
2908625
48.

Modification of the binding site(s) of lectins by an affinity column carrying an activated galactose-terminated ligand.

Moroney SE, D'Alarcao LJ, Goldmacher VS, Lambert JM, Blättler WA.

Biochemistry. 1987 Dec 15;26(25):8390-8.

PMID:
3442663
49.

Somatic cell mutants resistant to ricin, diphtheria toxin, and to immunotoxins.

Goldmacher VS, Anderson J, Schulz ML, Blättler WA, Lambert JM.

J Biol Chem. 1987 Mar 5;262(7):3205-9.

50.

The antileukemic efficacy of an immunotoxin composed of a monoclonal anti-Thy-1 antibody disulfide linked to the ribosome-inactivating protein gelonin.

Scott CF Jr, Goldmacher VS, Lambert JM, Chari RV, Bolender S, Gauthier MN, Blättler WA.

Cancer Immunol Immunother. 1987;25(1):31-40.

PMID:
3496157

Supplemental Content

Loading ...
Support Center